Recent News

• 06.09.2026 - Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
• 05.27.2026 - Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
• 05.20.2026 - Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
• 05.11.2026 - Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
• 05.06.2026 - Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
• 04.30.2026 - Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
• 03.31.2026 - Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

Recent Filings

• 05.20.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.11.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.11.2026 - ARS Annual Report to Security Holders
• 05.11.2026 - DEF 14A Other definitive proxy statements
• 05.11.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]